- Home
- Publications
- Publication Search
- Publication Details
Title
Neutralizing antibodies targeting SARS-CoV-2 spike protein
Authors
Keywords
COVID-19, SARS-CoV-2, Spike RBD, Therapeutic antibody, Antibody germline
Journal
Stem Cell Research
Volume 50, Issue -, Pages 102125
Publisher
Elsevier BV
Online
2020-12-16
DOI
10.1016/j.scr.2020.102125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID-19: the gendered impacts of the outbreak
- (2020) Clare Wenham et al. LANCET
- Convalescent plasma as a potential therapy for COVID-19
- (2020) Long Chen et al. LANCET INFECTIOUS DISEASES
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Structural basis for RNA replication by the SARS-CoV-2 polymerase
- (2020) Quan Wang et al. CELL
- Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19
- (2020) Gregory D. Sempowski et al. CELL
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
- (2020) Daniel Wrapp et al. CELL
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
- (2020) Vanessa Monteil et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- Serum IgA, IgM, and IgG responses in COVID-19
- (2020) Huan Ma et al. Cellular & Molecular Immunology
- Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
- (2020) Xiangyu Chen et al. Cellular & Molecular Immunology
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- (2020) Chenguang Shen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- The race for coronavirus vaccines: a graphical guide
- (2020) Ewen Callaway NATURE
- Cell entry mechanisms of SARS-CoV-2
- (2020) Jian Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients
- (2020) Kai Duan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
- (2020) Yan Wu et al. SCIENCE
- A human monoclonal antibody blocking SARS-CoV-2 infection
- (2020) Chunyan Wang et al. Nature Communications
- Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
- (2020) Changhai Lei et al. Nature Communications
- Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro
- (2020) Xiaoyan Pan et al. ANTIVIRAL RESEARCH
- Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
- (2020) Christoph Kreer et al. CELL
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
- (2020) Yunlong Cao et al. CELL
- Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
- (2020) Emilie Seydoux et al. IMMUNITY
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
- (2020) Seth J. Zost et al. NATURE MEDICINE
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
- (2020) Jiangdong Huo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
- (2020) Kui K. Chan et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
- (2020) Zhe Lv et al. SCIENCE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- Broad neutralization of SARS-related viruses by human monoclonal antibodies
- (2020) Anna Z. Wec et al. SCIENCE
- Structural basis of a shared antibody response to SARS-CoV-2
- (2020) Meng Yuan et al. SCIENCE
- Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
- (2020) Supriya Ravichandran et al. Science Translational Medicine
- Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2
- (2020) Alex Renn et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
- (2020) Jinkai Wan et al. Cell Reports
- TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
- (2020) Dorothea Bestle et al. Life Science Alliance
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- Antibodies may curb pandemic before vaccines
- (2020) Jon Cohen SCIENCE
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
- (2020) Leo Hanke et al. Nature Communications
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
- (2019) Shuai Xia et al. Science Advances
- Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells
- (2018) Jean Kaoru Millet et al. VIROLOGY
- Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control
- (2015) Michael S. Diamond et al. CELL
- Rare antibodies from combinatorial libraries suggests an S.O.S. component of the human immunological repertoire
- (2011) Richard A. Lerner Molecular BioSystems
- Structures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common Theme
- (2008) Judith M. White et al. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started